Cancer and blood coagulation: Molecular aspects

Cancer Journal from Scientific American

Volumn 5, Issue 3, 1999, Pages 132-138

  Bromberg, Michael E ^a   Cappello, Michael ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOPLASTIN;

BLOOD CLOTTING; CANCER; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; THROMBOGENESIS; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; DRUG DESIGN; FACTOR XA; HUMANS; NEOPLASMS; THROMBIN; THROMBOPLASTIN;

EID: 0033044220     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Trousseau A. Phlegmasia alba dolens. Clinique Medicale de l'Hotel-Dieu de Paris. The New Sydenham Society 1865;3:94-96.
2. Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983;62:14-31.
3. Zacharski LR, Ornstein DL. Heparin and cancer. Thromb Haemost 1998;80:10-23.
4. Nemerson Y. Tissue factor and hemostasis. Blood 1988;71:1-8.
5. Broze GJ. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 1995;46:103-112.
6. Murray JC. Coagulation and cancer. Br J Cancer 1991;64:422-424.
7. Billroth T. Lectures on surgical pathology and therapeurics. The New Sydenham Society 1878:355.
8. Zacharski LR, Dunwiddie C, Nutt EM et al. Cellular localization of activated factor X by Xa specific probes. Thromb Haemost 1991;65:545-548.
9. Dvorak HF, Senger DR, Dvorak AM. Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metastasis Rev 1983;2:41-73.
10. Gunji Y, Gorelik E. Role of fibrin coagulation in prorection of murine tumor cells from destruction by cytotoxic cells. Cancer Res 1988;48:5216-5221.
11. Orlander JV, Bremer ME, Marasa JC et al. Fibrin-enhanced endothelial cell organization. J Cell Physiol 1985;125:1-9.
12. O'Meara RA. Coagulative properties of cancer. Irish J Med Sci 1958;6:474-479.
13. Rao LVM. Tissue factor as a tumor procoagulant. Cancer Metastasis Rev 1992;11:249-266.
14. Paborsky LR, Caras IW, Fisher KL. Lipid association, but not the transmembrane domain, is required for tissue factor activity: substitution of the transmembrane domain with a phosphatidylinositol anchor. J Biol Chem 1991;266:21911-21916.
15. Zioncheck TF, Roy S, Behar GA. The cytoplasmic domain of tissue factor is phosphorylated by a protein kinase C-dependent mechanism. J Biol Chem 1992;267:3561-3564.
16. Mody RS, Carson SD. Tissue factor cytoplasmic domain peptide is multiply phosphorylated in vitro. Biochem 1997;36:7869-7875.
17. Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 1990;87:6934-6938.
18. Callander NS, Varki N, Rao LVM. Immunohistochemical identification of tissue factor in solid tumors. Cancer 1992;70:1194-1201.
19. Mueller BM, Reisfield RA, Edgington T et al. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA 1992;89:11832-11836.
20. Hu T, Bach RR, Horton R et al. Procoagulant activity in cancer cells is dependent on tissue factor expression. Oncology Res 1994;6:321-327.
21. Bromberg ME, Konigsberg WH, Madison JF et al. Tissue factor promotes metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci USA 1995;92:8205-8209.
22. Shigemor C, Wada H, Matsumoto K et al. Tissue factor expression and metastatic potential of colorectal cancer. Thromb Haemost 1998;80:894-898.
23. Mueller BM, Ruf W. Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis. J Clin Invest 1998;101:1372-1378.
24. Bromberg ME, Sundaram R, Homer RJ et al. Role of tissue factor in metastasis: function of die cytoplasmic and extracellular domains of the molecule. Thromb Haemost 1999;in press.
25. Ott I, Fischer EG, Miyagi Y et al. A role for tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280. J Cell Bio 1998;140:1241-1253.
26. 2+ oscillations in Madin-Darby canine kidney cells only when proreolytically active. J Biol Chem 1996;271:29034-29042.
27. Masuda M, Nakamura S, Murakami T et al. Association of tissue factor with a gamma-chain homodimer of the IgE receptor-type I in cultured human monocytes. Eur J Immunol 1996;26:2529-2532.
28. Poulsen LK, Jacobsen N, Sorensen NCH et al. Signal transduction via the mitogen-activated protein kinase pathway induced by binding of coagulation factor VIIa to tissue factor. J Biol Chem 1998;273:6228-6232.
29. Pendurthi UR, Alok D, Rao LVM. Binding of factor VIIa to tissue factor induces alterations in gene expression in human fibroblast cells: up-regulation of poly(A) polymerase. Proc Natl Acad Sci USA 1997;94:12598-12603.
30. Taniguchi T, Kakkar AK, Tuddenham EGD et al. Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer. Cancer Res 1998;58:4461-4467.
31. Zhang Y, Deng Y, Luther T et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994;94:1320-1327.
32. Toomey JR, Kratzer KE, Lasky NM et al. Effect of tissue factor deficiency on mouse and tumor development. Proc Natl Acad Sci USA 1997;94:6922-6926.
33. Shoji M, Hancock WW, Abe K et al. Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial cell growth factor in human cancer. Am J Pathol 1998;152:399-411.
34. Contrino J, Hair GA, Kreutzer DL et al. In situ detection of the expression of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nature Med 1996;2:209-215.
35. Davie EW. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 1995;74:1-6.
36. Leytus SP, Foster DC, Durachi K et al. Gene for human factor X: a blood coagulation factor whose gene is essentially identical with that of factor DC and protein C. Biochemistry 1986;25:5098-5102.
37. Falanga A, Gordon SG. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochemistry 1985;24:5558-5567.
38. Tuszynski GP, Gasic TB, Gasic GJ. Isolation and characterization of antistasin: an inhibitor of metastasis and coagulation. J Biol Chem 1987;262:9718-9723.
39. Kakkar AK, Lemoine NR, Stone SR et al. Identification of a thrombin receptor with factor Xa receptor and tissue factor in human pancreatic carcinoma cells. Clin Molec Pathol 1995;48:M288-M290.
40. Adida C, Ambrosini G, Plescia J et al. Protease receptors in Hodgkin's disease: expression of the factor Xa receptor, effector cell protease receptor-1, in Reed-Sternberg cells. Blood 1996;88:1457-1464.
41. Donnelly KM, Bromberg ME, Milstone A et al. Ancylostoma caminum anticoagulant peptide blocks metastasis in vivo and inhibits factor Xa binding to melanoma cells in vitro. Thromb Haemost 1998;79:1041-1047.
42. Cappello M, Vlasuk GP, Bergum PW et al. Ancylostoma caninum anticoagulant pepdde: an inhibitor of coagulation factor Xa. Proc Natl Acad Sci USA 1995;92:6152-6156.
43. Sakai T, Kisiel W. Binding of human factors X and Xa to Hep G2 and J82 human tumor cell lines: evidence that factor Xa binds to tumor cells independent of factor Va. J Biol Chem 1990;265:9105-9113.
44. Kazama Y, Komiyama Y, Kisiel W. Tissue factor pathway inhibitor and protease nexin-1 are major factor Xa binding proteins on the HepG2 cell surface. Blood 1993;81:676-682.
45. Gajdusek C, Carbon S, Ross R et al. Activation of coagulation releases endothelial cell mitogens. J Cell Biol 1986;103:419-428.
46. Gasic GP, Arenas CP, Gasic TB et al. Coagulation factors X, Xa, and protein S are potent mitogens of cultured aortic smooth muscle cells. Proc Natl Acad Sci USA 1992;89:2317-2320.
47. Nicholson AC, Nachman RL, Altieri DA et al. Effector cell protease receptor-1 is a vascular receptor for coagulation factor Xa. J Biol Chem 1996;271:28407-28413.
48. Cirino G, Cicala C, Bucci M et al. Factor Xa as an interface between coagulation and inflammation: molecular mimicry of factor Xa association with effector cell protease receptor-1 induces acute inflammation in vivo. J Clin Invest 1997;99:2446-2451.
49. Papatropoulos A, Piccardoni P, Cirino G et al. Hypotension and inflammatory cytokine gene expression triggered by factor Xa-nitric oxide signaling. Proc Natl Acad Sci USA 1998;95:4738-4742.
50. Esumi N, Fan D, Fidler IJ. Inhibition of murine melanoma experimental metastasis by recombinant disulfatohirudin, a highly specific thrombin inhibitor. Cancer Res 1991;51:4549-4556.
51. Fischer EG, Ruf W, Mueller BM. Tissue factor-initiated thrombin generation activates the thrombin receptor on malignant melanoma cells. Cancer Res 1995;55:1629-1632.
52. Fenton JW II, Fasco MJ, Strackrow AB et al. Human thrombins: production, evaluation, and properties of α thrombin. J Biol Chem 1977;252:3587-3598.
53. Day O, Corvera CU, Steinhoff M et al. Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. Am J Physiol 1998;274:C1429-C1452.
54. Vu TKH, Hung DT, Wheaton VI et al. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991;64:1057-1068.
55. Grand RJA, Turnell AS, Grabham PW. Cellular consequences of thrombin-receptor activation. Biochem J 1996;313:353-368.
56. Wojtukiewicz MZ, Tang DG, Ben-Josef E. Solid tumor cells express functional "tethered ligand" thrombin receptor. Cancer Res 1995;55:698-704.
57. Nierodzik MLR, Bain RM, Lin DC Presence of the seven transmembrane thrombin receptor on human tumour cells: effect of activation on tumour adhesion to platelets and tumour tyrosine phosphorylation. Br J Haematology 1996;92:452-457.
58. Nierodzik MLR, Kajumo F, Karpatkin S. Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo. Cancer Res 1992;52:3267-3272.
59. Nierodzik ML, Chen K, Takeshita K et al. Protease-activated receptor-1 (PAR-1) is required and rate limiting for thrombin-enhanced experimental pulmonary metastasis. Blood 1998;92:3694-3700.
60. Even-Ram S, Uziely B, Cohon P. Thrombin receptor overexpression in malignant and physiological invasion processes. Nature Med 1998;4:909-914.
61. Kaufmann R, Schafberg H, Rudroff C. Thrombin receptor activation results in calcium signaling and protein kinase C-dependent stimulation of DNA synthesis in Hep-2g laryngeal carcinoma cells. Cancer 1997;80:2068-2074.
62. Chiang HS, Yang RS, Lin SW. Tissue factor activity of SW-480 human colon adenocarcinoma cells is modulated by thrombin and protein kinase C activation. Br J Cancer 1998;78:1121-1127.
63. Zacharski LR, Meehan KR. Anticoagulants and cancer therapy. Cancer J Sci Am 1995;6:16-20.
64. Chahininn AP, Propert KJ, Ware JH et al. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol 1989;7:993-1002.
65. Lensing AWA, Prins MH, Davidson BL et al. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 1995;155:601-607.
66. Siragusa S, Cosmi B, Piovella F et al. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996;100:269-277.
67. Ruf W, Edgington TS. An anti-tissue factor monoclonal antibody which inhibits TF-VIIa complex is a potent anticoagulant in plasma. Thromb Haemost 1991;66:529-533.
68. Fiore MM, Neuenschwander PF, Morrissey JH. An unusual antibody that blocks tissue factor/factor VIIa function by inhibiting cleavage only of macromolecular substrates. Blood 1992;80:3127-3134.
69. Wun TC, Kretzmer KK, Palmier MO et al. Comparison of recombinant tissue faaor pathway inhibitors expressed in human SK hepatoma, mouse C127, baby hamster kidney, and Chinese hamster ovary cells. Thromb Haemost 1992;68:54-59.
70. Johnson PH. Hirudin: clinical potential of a thrombin inhibitor. Annu Rev Med 1994;45:165-177.
71. 2 ((3-methyl-1,2,3,4-tetrahydro-8-quinolony)sulfonyl)-arginyl]-2-piperidine carboxylic acid. Biochemistry 1984;23:85-90.
72. Tapparelli C, Metternich R, Ehrhardt C et al. Synthetic low-molecular-weight thrombin inhibitors: molecular design and pharmacological profile. Trends Pharmacol Sci 1993;14:366-376.
73. Cook JJ, Sitko GR, Bednar B et al. An antibody to the exosite of the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey. Circulation 1995;91:2961-2971.
74. Rebello SS, Blank HS, Rote WE et al. Antithrombotic efficacy of a recombinant nematode anticoagulant peptide (rNAP5) in canine models of thrombosis after single subcutaneous administration. J Pharmacol Exp Ther 1997;283:91-99.